EUVIMEDEUVIMED entdecken
Crossref

A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening

Xiao-Han Fan, Yang Zhang, Pei Wang, Qian-Qian Song, Mona Wang, Raquel Mejias-Luque, Zhe-Xuan Li, Tong Zhou, Jing-Ying Zhang, Wei-Dong Liu, Lan-Fu Zhang, Wen-Qing Li und 5 weitere

International Journal of Cancer · 2024

DOI: 10.1002/ijc.34739 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Xiao-Han Fan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Cancer Epidemiology, Peking University Can…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Helicobacter pylori, Helicobacter Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS), International (regional) Cooperation and Exchange Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective screening and early detection are critical to improve the prognosis of gastric cancer (GC). Our study aims to explore noninvasive multianalytical biomarkers and construct integrative models for preliminary risk assessment and GC detection. Whole genomewide methylation marker discovery was conducted with CpG tandems target amplification (CTTA) in cfDNA from large asymptomatic screening participants in a high‐risk area of GC. The methylation and mutation candidates were validated simultaneously using one plasma from patients at various gastric lesion stages by multiplex profiling with Mutation Capsule Plus (MCP). Helicobacter pylori specific antibodies were detected with a recomLine assay. Integrated models were constructed and validated by the combination of multianalytical biomarkers. A total of 146 and 120 novel methylation markers were found in CpG islands and promoter regions across the genome with CTTA. The methylation markers together with the candidate mutations were validated with MCP and used to establish a 133‐methylation‐marker panel for risk assessment of suspicious precancerous lesions and GC cases and a 49‐methylation‐marker panel as well as a 144‐amplicon‐mutation panel for GC detection. An integrated model comprising both methylation and specific antibody panels performed better for risk assessment than a traditional model (AUC, 0.83 and 0.63, P < .001). A second model for GC detection integrating methylation and mutation panels also outperformed the traditional model (AUC, 0.82 and 0.68, P = .005). Our study established methylation, mutation and H. pylori ‐specific antibody panels and constructed two integrated models for risk assessment and GC screening. Our findings provide new insights for a more precise GC screening strategy in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsHelicobacter pyloriHelicobacter InfectionsHumansDNA MethylationEarly Detection of CancerBiomarkersRisk AssessmentBiomarkers, TumorCpG Islands

Stichwörter der Autor:innen

biomarkergastric cancermethylationmutationprecancerous lesions

Substanzen

BiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, Beijing, China.
  • PYLOTUM Key Joint Laboratory for Upper GI Cancer, Technische Universität München/Peking University Cancer Hospital & Institute, Munich, Germany.
  • PYLOTUM Key Joint Laboratory for Upper GI Cancer, Technische Universität München/Peking University Cancer Hospital & Institute, Beijing, China.
  • State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Technical University of Munich (TUM), School of Medicine, Institute for Medical Microbiology, Immunology and Hygiene, Munich, Germany.
  • German Center for Infection Research, Munich, Germany.

ORCID-Profile: Xiao-Bing Wang, Kai-Feng Pan

Förderung

  • Beijing Natural Science Foundation
  • Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS)
  • International (regional) Cooperation and Exchange Project
  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality
  • National Key Research and Development Program of China

Zitieren

APA

Fan, X. H., Zhang, Y., Wang, P., Song, Q. Q., Wang, M., Mejias-Luque, R., Li, Z. X., Zhou, T., Zhang, J. Y., Liu, W. D., Zhang, L. F., Li, W. Q., You, W. C., Gerhard, M., Jiao, Y. C., Wang, X. B., & Pan, K. F. (2024). A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening. International Journal of Cancer. https://doi.org/10.1002/ijc.34739

Vancouver

Fan XH, Zhang Y, Wang P, Song QQ, Wang M, Mejias-Luque R, et al. A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening. International Journal of Cancer. 2024. doi:10.1002/ijc.34739

BibTeX
@article{Fan2024,
  author = {Fan, Xiao-Han and Zhang, Yang and Wang, Pei and Song, Qian-Qian and Wang, Mona and Mejias-Luque, Raquel and Li, Zhe-Xuan and Zhou, Tong and Zhang, Jing-Ying and Liu, Wei-Dong and Zhang, Lan-Fu and Li, Wen-Qing and You, Wei-Cheng and Gerhard, Markus and Jiao, Yu-Chen and Wang, Xiao-Bing and Pan, Kai-Feng},
  title = {A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening},
  journal = {International Journal of Cancer},
  year = {2024},
  doi = {10.1002/ijc.34739}
}
Kostenlos starten →